Atamyo Therapeutics SAS has received clinical trial application (CTA) authorizations in Italy and France for ATA-200, its gene therapy for the treatment of γ-sarcoglycan related limb-girdle muscular dystrophy type 2C/R5 (LGMD2C/R5).

Microglia is known to play a crucial role in brain homeostasis, but this is lost during neurodegeneration.

Nurexone Biologic Inc. has signed a strategic service agreement with Vivox Ltd. for large-scale animal testing of Exopten therapy for spinal cord injury (SCI).

To address the need for novel therapeutic candidates against Duchenne muscular dystrophy (DMD), investigators at Mitorx Therapeutics Ltd. developed a library of novel small-molecule mitochondriotropic agents.

Galectin-3 (Gal-3) is used as a marker of activated microglia, and thus a protein that drives inflammation. Patients with Alzheimer’s disease (AD) have shown increased levels of Gal-3 in their cerebrospinal fluid (CSF) compared to healthy controls, as well as increased expression in their brain tissue.

Leucine-rich repeat kinase 2 (LRRK2), a key drug target, plays a major role in Parkinson’s disease (PD). Mutations in LRRK2, specifically LRRK2 G2019S which increases LRRK2 kinase activity, have been observed in a majority of PD patients.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with the University of Oxford to verify drug discovery seeds and obtain screening compounds for the creation of new medicines.